[go: up one dir, main page]

GB9709084D0 - Methods of inhibiting immune-complex diseases - Google Patents

Methods of inhibiting immune-complex diseases

Info

Publication number
GB9709084D0
GB9709084D0 GBGB9709084.9A GB9709084A GB9709084D0 GB 9709084 D0 GB9709084 D0 GB 9709084D0 GB 9709084 A GB9709084 A GB 9709084A GB 9709084 D0 GB9709084 D0 GB 9709084D0
Authority
GB
United Kingdom
Prior art keywords
methods
complex diseases
inhibiting immune
immune
inhibiting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GBGB9709084.9A
Other versions
GB2312844A (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of GB9709084D0 publication Critical patent/GB9709084D0/en
Publication of GB2312844A publication Critical patent/GB2312844A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GB9709084A 1996-05-07 1997-05-06 A naphthyl compound for the treatment of immune-complex diseases Withdrawn GB2312844A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1702496P 1996-05-07 1996-05-07

Publications (2)

Publication Number Publication Date
GB9709084D0 true GB9709084D0 (en) 1997-06-25
GB2312844A GB2312844A (en) 1997-11-12

Family

ID=21780303

Family Applications (1)

Application Number Title Priority Date Filing Date
GB9709084A Withdrawn GB2312844A (en) 1996-05-07 1997-05-06 A naphthyl compound for the treatment of immune-complex diseases

Country Status (1)

Country Link
GB (1) GB2312844A (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999007377A1 (en) 1997-08-07 1999-02-18 Eli Lilly And Company 1-[4-(substituted alkoxy)benzyl]naphthalene compounds having estrogen inhibitory activity

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7501441B1 (en) * 1994-09-20 2009-03-10 Eli Lilly And Company Naphthyl compounds, intermediates, processes, compositions, and methods

Also Published As

Publication number Publication date
GB2312844A (en) 1997-11-12

Similar Documents

Publication Publication Date Title
GB9824436D0 (en) Methods of treatment
HU9403657D0 (en) Methods of inhibiting pulmonary hypertenzive diseases
EP1033994A4 (en) Methods of preparation of bioginkgo
IL115015A0 (en) Methods of inhibiting demyelinating and desmyelinating diseases
ZA9410083B (en) Methods of inhibiting autoimmune diseases
ZA9410088B (en) Methods of inhibiting breast disorders
EP1017459A4 (en) Game of chance
HU9700071D0 (en) Use of muramilpeptides
PL336579A1 (en) Treatment of diseases associated with cytokinins
EP1039883A4 (en) Methods for the treatment of apolipoprotein e related diseases
HU9702480D0 (en) New polymorphe modification of doxazosin-mesylate
GB2328397B (en) Manufacture of elongate members
CY2590B2 (en) Preparation of 1-butyl-4-piperidinylmethylamine
HU9702479D0 (en) New polymorphe modification of doxazosin-mesylate
IL112839A0 (en) Methods for the purification of halofluorocarbons
GB9709084D0 (en) Methods of inhibiting immune-complex diseases
GB2306873B (en) Manufacture of heaters
NZ295530A (en) Preparation of 1-halo-3-trialkylsilanyl-benzenes
SG64924A1 (en) Inhibiting photodecompostion of 3-substituted-2- oxindoles
PL313849A1 (en) Beta-aminoesters of o-hydrobenzylamides
GB9701448D0 (en) Methods of treatment
GB9602404D0 (en) Methods of treatment
GB9725593D0 (en) Method of ornamentation
GB9824791D0 (en) Novel methods of treatment
GB9710054D0 (en) Treatment of diseases

Legal Events

Date Code Title Description
WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)